Integral Diagnostics Ltd · ASX:IDX
Integral Diagnostics — Shareholder Meeting (November 2024)
10 slides from Integral Diagnostics's shareholder meeting presentation, Nov 1, 2024
Slide 1: 2024 Annual General Meeting – Chair's Address and Presentation
Integral Diagnostics Limited 2024 Annual General Meeting – Chair’s Address and Presentation Ladies and gentlemen, I am very pleased to be addressing you today at my first AGM as Chair. Integral Diagnostics is a health care company built on excellent foundations. Our services dramatically improve the
Slide 2: Chair's address: proposed merger with Capitol Health and governance
Within the legal constraints on IDX and Capitol prior to the merger being implemented, integration planning is well advanced to enable the combined group to take advantage of the opportunities presented by the merger. We understand that effective cultural alignment is one of the most important facto
Slide 3: Chair's address: governance and sustainability
Last year, we also welcomed Ingrid Player as a Non-Executive Director. In April this year, the Board determined to split the Audit and Risk Committee into two separate committees – an Audit Committee which continues to be well chaired by Raelene Murphy; and a new Risk, Compliance and Sustainability
Slide 4: Chair's closing thanks
I take this opportunity to thanks my fellow directors, IDX’s leadership team and you, our shareholders, for your continued support. Toby Hall Chair For personal use only 4
Slide 5: Chair Address
For personal use only CHAIR ADDRESS Toby Hall - Chair
Slide 6: FY24 Financial Highlights
FY24 FINANCIAL HIGHLIGHTS Solid revenue and Operating EBITDA growth of 6.6% and 7.4% respectively, with an improvement in operating EBITDA margin to 19.5% (FY23: 19.3%) 1.3% 7.4% 1.0% 6.6% 5.5% Net debt / EBITDA Statutory NPAT increase in increase in increase in increase in free For personal use onl
Slide 7: Historical Performance
HISTORICAL PERFORMANCE Operating Revenue Operating EBITDA 500.0 469.7 100.0 93.5 91.5 440.8 85.2 450.0 90.0 For personal use only 400.0 80.0 75.7 74.8 348.8 358.7 350.0 70.0 300.0 274.1 AUD $ms 60.0 AUD $ms 250.0 50.0 200.0 40.0 150.0 30.0 100.0 20.0 50.0 10.0 - - FY20 FY21 FY22 FY23 FY24 FY20 FY21
Slide 8: Proposed Merger with Capitol Health
PROPOSED MERGER WITH CAPITOL HEALTH Highly complementary geographic footprints totaling 151 DI sites • Combined business expected to be a market For personal use only 90 Total IDX sites leader in DI in Australia and New Zealand. 61 Total CAJ sites • Merged group to be led by IDX CEO Dr Ian Kadish. I
Slide 9: Governance
GOVERNANCE • A well-managed process of Board renewal has been executed. • IDX is actively recruiting amongst our outstanding radiologists for a replacement for a For personal use only Radiologist Executive Director to ensure a specialist medical perspective is an intrinsic part of our decision makin
Slide 10: Sustainability
SUSTAINABILITY FY24 ESG Report highlights include: • Gap analysis of the Australian Sustainability Reporting Standards which will come into effect For personal use only next year and completing our roadmap for ASRS implementation. • Quantification and disclosure of IDX’s total Scope 1 and Scope 2 em
Integral Diagnostics — Shareholder Meeting (November 2024) on 6ix